Brown A S, Hong Y, de Belder A, Beacon H, Beeso J, Sherwood R, Edmonds M, Martin J F, Erusalimsky J D
Department of Cardiology, King's College School of Medicine and Dentistry, London, UK.
Arterioscler Thromb Vasc Biol. 1997 Apr;17(4):802-7. doi: 10.1161/01.atv.17.4.802.
Altered platelet morphology and function have been reported in patients with diabetes. They are likely to be associated with the pathological processes and increased risk of vascular disease seen in these patients. Mean platelet volume (MPV), platelet count, and megakaryocyte (MK) ploidy (DNA content) were measured in (1) nondiabetics with normal coronary arteries, (2) nondiabetics with coronary artery atherosclerosis, (3) diabetics without evidence of vascular complications, and (4) diabetics with vascular disease. The platelet count (+/- SD) was increased in all groups but only significantly in the diabetics with vascular disease (236 +/- 65 versus 250 +/- 54 versus 257 +/- 64 versus 295 +/- 90 [P < or = .05] x 10(9)/L, for groups, I, II, II, and IV, respectively). The MPV was significantly increased in patients with atherosclerosis (7.0 +/- 0.4 versus 8.0 +/- 1.2 [P < or = .05] versus 7.2 +/- 0.9 versus 8.1 +/- 0.9 [P < or = .05] IL). Geometric mean MK ploidy was significantly increased in all groups compared with controls (16 +/- 1.5 versus 18.7 +/- 1.8 [P < or = .05] versus 19.8 +/- 1.6 [P < or = .05] versus 20.1 +/- 2.7 [P < or = .05]). Furthermore, some patients with vascular disease and/or diabetes had a modal ploidy shift from 16 (the normal mammalian modal ploidy) to 32, with a concomitant reduction of MKs in the 8 and 16 ploidy classes. This shift was seen particularly in the diabetics with vascular disease (P = .007). Interleukin-6 (IL-6) levels were measured and were elevated in patients with atherosclerosis; the highest levels were found in the diabetic patients (0.7 +/- 0.9 versus 5.3 +/- 5.5 [P < or = .05] versus 2.5 +/- 2.8 versus 6.7 +/- 5.5 [P < or = .05] ng/L). In the diabetic patients with atherosclerosis, fibrinogen levels were also increased (2.85 +/- 0.76 versus 3.34 +/- 1.32 versus 2.43 +/- 1.50 versus 5.59 +/- 1.72 [P < or = .05] g/L). Furthermore, IL-6 levels correlated with MK ploidy (r = .45, P = .009) and fibrinogen levels (r = .5, P = .0001). This study demonstrates that patients with vascular disease, particularly diabetics, have an altered MK ploidy distribution, showing a shift toward higher ploidy in association with an increased platelet mass (count x volume). Changes in platelets in diabetes probably reflect MK changes, which themselves are a response to systemic change.
糖尿病患者中已报道有血小板形态和功能改变。它们可能与这些患者中所见的病理过程及血管疾病风险增加有关。对以下几组人群测量了平均血小板体积(MPV)、血小板计数和巨核细胞(MK)倍性(DNA含量):(1)冠状动脉正常的非糖尿病患者;(2)患有冠状动脉粥样硬化的非糖尿病患者;(3)无血管并发症证据的糖尿病患者;(4)患有血管疾病的糖尿病患者。所有组的血小板计数(±标准差)均升高,但仅患有血管疾病的糖尿病患者显著升高(分别为236±65对250±54对257±64对295±90[P≤0.05]×10⁹/L,对应组I、II、III和IV)。动脉粥样硬化患者的MPV显著升高(7.0±0.4对8.0±1.2[P≤0.05]对7.2±0.9对8.1±0.9[P≤0.05]飞升)。与对照组相比,所有组的几何平均MK倍性均显著升高(16±1.5对18.7±1.8[P≤0.05]对19.8±1.6[P≤0.05]对20.1±2.7[P≤0.05])。此外,一些患有血管疾病和/或糖尿病的患者出现了模式倍性从16(正常哺乳动物模式倍性)转变为32的情况,同时8倍体和16倍体类别的MK数量减少。这种转变在患有血管疾病的糖尿病患者中尤为明显(P = 0.007)。测量了白细胞介素-6(IL-6)水平,动脉粥样硬化患者的该水平升高;糖尿病患者中水平最高(0.7±0.9对5.